Basic information Safety Related Supplier

ChemicalBook Product Catalog Imiglitazar

1/1

Imiglitazar NEW

$700.00 1mg

$1800.00 5mg

Min. Order
Purity97.33%
Cas No250601-04-8
Supply Ability10g
Update time2026-04-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP2Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Imiglitazar
CAS No	250601-04-8
EC-No
Min. Order
Purity	97.33%
Supply Ability	10g
Release date	2026/04/13

Product Introduction

Bioactivity

Name	Imiglitazar
Description	Imiglitazar (TAK559) is a potent PPAR-β/δ receptor agonist with hypoglycemic effects.
In vitro	TAK-559, a partial agonist for hPPARg1, achieves approximately 68% of the maximal activation obtained with rosiglitazone, a known PPARγ agonist. Significant activation of PPARγ is observed at a high concentration (10 μM) of TAK-559. Competition-binding assays using radiolabeled ligand indicate that the transactivation of all hPPAR subtypes by TAK-559 is a result of direct binding of TAK-559 to each subtype. TAK-559 also recruits the coactivator SRC-1 to both hPPARγ1 and hPPARα, and dissociates the corepressor NCoR from both hPPARγ1 and hPPARα[1]. In the presence of 10 μM TAK-559, TNFα- or IL-1β-induced THP-1 cell attachment to cultured endothelial cells is significantly reduced. The secretion of monocyte chemoattractant protein-1 (MCP-1) from endothelial cells is reduced by 36%, accompanied by decreased mRNA expression in the cells. Furthermore, the proliferation and migration of cultured smooth muscle cells are significantly decreased in the presence of TAK-559[3].
In vivo	During TAK-559 treatment, significant elevation of circulating high-density lipoprotein (HDL) cholesterol levels is observed, characterized by an increase in large HDL particles and a decrease in small dense HDL particles. Concurrently, plasma triglyceride and apolipoprotein B-100 levels decrease, while apolipoprotein A-I increases. Hyperinsulinemia and insulin resistance are significantly corrected with the highest dose of 3.0 mg/kg per day in these prediabetic monkeys. Additionally, no adverse effects on representative liver function parameters are observed during the study period[2].
Storage	Shipping with blue ice/Shipping at ambient temperature.
Keywords	TAK559 \| TAK 559 \| PPARδ \| PPARγ1 \| PPARβ \| PPARα \| Imiglitazar
Inhibitors Related	PHYTOL \| Rosiglitazone \| Retinoic acid \| Daidzein \| Fenofibrate \| Magnesium acetate tetrahydrate \| Maltitol \| Naringenin \| 2,3-Butanediol \| NPC 15199 \| Icariin \| Cloxiquine

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy